HQE1 logo

CytosorbentsDB:HQE1 Stock Report

Market Cap €55.2m
Share Price
€0.86
My Fair Value
€4.12
79.2% undervalued intrinsic discount
1Y-8.5%
7D-1.9%
Portfolio Value
View

Cytosorbents (HQE1) Stock Overview

Engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. More details

HQE1 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

HQE1 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Cytosorbents Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cytosorbents
Historical stock prices
Current Share PriceUS$0.86
52 Week HighUS$1.36
52 Week LowUS$0.66
Beta1.2
1 Month Change-12.12%
3 Month Change-6.35%
1 Year Change-8.55%
3 Year Change-57.10%
5 Year Change-89.23%
Change since IPO-77.31%

Recent News & Updates

Recent updates

Shareholder Returns

HQE1DE Medical EquipmentDE Market
7D-1.9%-0.5%0.4%
1Y-8.5%-12.6%18.3%

Return vs Industry: HQE1 exceeded the German Medical Equipment industry which returned -12.3% over the past year.

Return vs Market: HQE1 underperformed the German Market which returned 19.3% over the past year.

Price Volatility

Is HQE1's price volatile compared to industry and market?
HQE1 volatility
HQE1 Average Weekly Movement16.5%
Medical Equipment Industry Average Movement6.4%
Market Average Movement5.1%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.6%

Stable Share Price: HQE1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: HQE1's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1997149Phil Chanwww.cytosorbents.com

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood.

Cytosorbents Corporation Fundamentals Summary

How do Cytosorbents's earnings and revenue compare to its market cap?
HQE1 fundamental statistics
Market cap€55.16m
Earnings (TTM)-€13.78m
Revenue (TTM)€30.22m
1.8x
P/S Ratio
-4.0x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HQE1 income statement (TTM)
RevenueUS$35.33m
Cost of RevenueUS$10.87m
Gross ProfitUS$24.46m
Other ExpensesUS$40.57m
Earnings-US$16.11m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin69.23%
Net Profit Margin-45.59%
Debt/Equity Ratio97.6%

How did HQE1 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/21 14:51
End of Day Share Price 2025/07/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytosorbents Corporation is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffBrean Capital
Jason KolbertD. Boral Capital LLC.
Sean LeeH.C. Wainwright & Co.